Oxazole

Oxazoles have established itself as a valuable pharmacophore and structural element in small-molecule drug discovery. The oxazole ring's unique structure enables its derivatives to exert diverse weak interactions, including hydrogen bonds, coordination bonds, ion-dipole, cation-π, π-π stacking, and hydrophobic effects, and oxazole-based compounds therefore display extensively broad potential applications in medicinal chemistry, showing biological activities across antibacterial, antifungal, antiviral, antitubercular, anticancer, and anti-inflammatory areas. The electronic character of the 1,3-oxazole sits intermediate between furan and pyridine, providing a moderate hydrogen bond acceptor through the nitrogen while conferring useful aromatic stabilisation and metabolic resistance compared with more reactive five-membered rings. Oxazole functions as a bioisostere of thiazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles, as well as serving as a cyclic replacement for amide bonds, preserving the geometry and hydrogen bond character of the parent motif whilst improving lipophilicity and plasma metabolic stability.

The substitution flexibility at the 2-, 4-, and 5-positions of the oxazole ring allows broad SAR exploration. The scaffold is also found widely in natural product scaffolds, reinforcing its relevance as a starting point for drug discovery campaigns across oncology, anti-infective, CNS, and cardiovascular programmes. There are currently eight FDA-approved drugs bearing oxazole scaffolds available in the market, with antitumour activity representing one of the most notable areas of pharmacological activity among oxazole derivatives.

Examples of Oxazoles in the clinic include: Oxaprozin (Daypro), approved by the FDA in 1992 for the treatment of rheumatoid arthritis and osteoarthritis. Dalfopristin, approved by the FDA in 1999 as part of the combination Synercid, the first injectable streptogramin antibiotic, for the treatment of vancomycin-resistant Enterococcus faecium and serious Gram-positive infections, contains a 1,3-oxazole ring embedded within its polyunsaturated macrolactone that forms direct hydrophobic contacts with the ribosomal peptide exit tunnel at base A2451, contributing critically to its inhibition of bacterial protein synthesis at the early elongation stage.

Our range of Oxazoles features novel substitutions and the incorporation of synthetically tractable functional groups such as boronic acids and esters, amines, carboxylic acids, ketones, hydroxyls and halogens to enable expedient synthetic strategies.

Please examine a selection of Oxazoles in our catalogue. The full range can be found using the substructure feature of our Search tools.